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Table 1. Early febrile and documented infectious episodes among 54 HCT patients.
Febrile episodes DIE CDI MDI Bacteremia IFI
N episodes in all patients 24 14 1 4 10 0
Incidence per 100 patients (n5 54) 44 26 2 7 19 0
Incidence per 1000 neutropenia
days (n5737)
32 19 1 5 14 0
Specific presentation or pathogen N/A N/A Pneumonia Influenza A (n51),
CMV (n51), Clostridium
difficile (n51), Coagulase
negative staphylococci
Escherichia coli (n55), Stenotrophomonas
maltophilia (n51), Coagulase negative
staphylococci (n51), Staphylococcus
aurus (n51), Streptococcus pneumonia
(n51), Enterococcus (n51)
N/A
DIE – documented infectious episodes, CDI – clinical documented infections, MDI – microbiology documented infections, IFI – invasive fungal infections,
N/A – not applicable.
Poster Session II S347HCT. We hypothesized that early febrile or documented infectious
episodes (from day 0 through engraftment) would promote the de-
velopment of aGVHD. Data regarding febrile episodes (defined as
clinically and/or microbiologically documented infections or epi-
sodes with fever . 380C for two consecutive days to exclude drug
and blood-product-related fever) were prospectively collected for
patients undergoing HCT. In addition, all patients’ charts were ret-
rospectively reviewed for the onset, staging/grading of aGVHD and
for patient-donor characteristics. 54 consecutive patients undergo-
ing HCT were included. Median patient age was 51 (range, 22-67)
years. Preparative regimen was myeloablative (MA) (n 5 23) or re-
duced intensity (n 5 31) conditioning. 27 pts received peripheral
blood stem cells (PBSC) fromHLA-identical siblings, 25 patients re-
ceived PBSC from unrelated donors (19 HLA-matched PBSC and 6
received 1-HLA-Agmismatched PBSC) and 2 patients received dou-
ble umbilical cord blood graft. Post-grafting immunosuppression
consisted of combined cyclosporine with either methotrexate or my-
cophenolate mofetil. Patients receiving an unrelated donor graft
were also given ATG. By day 120, 34 pts (63%) developed grade
2-4 aGVHD. 24 pts developed febrile episode, 14 of whom had
documented infectious episodes (clinical documented infection,
n 5 1; microbiology documented infection, n 5 3 and bacteremia,
n 5 10).Patients who developed a febrile episode had a higher risk
for developing grade 2-4 (OR 5 5.7, 95% CI 1.6-20.8, p\ 0.05)
and grade 3-4 (OR 5 3, 95% CI 0.8-10.6, p 5 0.08) aGVHD.
Among other risk factors for aGVHD (MA conditioning, female do-
nor to male recipient, unrelated donor and 1-HLA-Ag mismatched
graft), only MA conditioning was associated with an increased risk
for aGVHD with borderline statistical significance (OR 5 2.8,
95%CI 0.8-9.5, p5 0.09).We conclude that febrile episodes occur-
ring early, before engraftment, are associated with higher risk for
GVHD. Confirmation of these findings in larger cohorts is war-
ranted. The types of infections possibly promoting aGVHD should
be defined.540
ETANERCEPT FOR STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST
DISEASE FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANS-
PLANTATION
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Suwon, Kyunggi-do, Korea
Treatment strategy for steroid-refractory acute graft-versus-host
disease (GvHD) after allogeneic hematopoietic stem cell transplan-
tation (allo-HSCT) needs to be standardized.We report our clinical
experience of the effect of etanercept on steroid-refractory acute
GvHD. A total of 18 consecutive patients with steroid-refractory
acute GvHD were retrospectively studied. Twenty-five milligrams
of etanercept were given subcutaneously twice weekly for four weeks.
Clinical responses were evaluated with regard to the severity of acute
GvHD. The median age of patients was 43.5 years. Before etaner-
cept, grade IV, grade III, grade II, and grade I acute GvHDoccurred
in seven, six, five, and zero patients, respectively; however the num-
ber of patients changed to four, five, five, and four, respectively, afteretanercept (p.005). Eighty percent of grade II, 14% of grade III, and
57% of grade IV patients showed a partial response. Skin and gut
GvHD were well controlled with etanercept, whereas hepatic
GvHD was not. Three patients died of fatal infection. There were
no factors affecting the clinical outcome of etanercept. All the
non-responders died and 56.6% of the responders survived
(p0.0008). Etanercept can be effective in treating steroid-refractory
acute GvHD after allo-HSCT, with tolerable side effects.541
THE ROLE OF PLASMA CYTOKINES IN THE DIAGNOSIS OF AUTOIMMUNE
PHENOMENA IN PATIENTS (PTS) WITH MULTIPLE MYELOMA (MM)
UNDERGOING NOVEL ANTI-MYELOMA THERAPIES AND AUTOLOGOUS
HEMATOPOIETIC CELL TRANSPLANTATION (AUTO-HCT)
Veeraputhiran, M., Sanath Kumar, N., Haider, S., Barlogie, B., Van
Rhee, F., Anaissie, E. University of Arkansas for Medical Sciences, Little
Rock, AR
Introduction: Auto-immune (AI) phenomena among MM patients
receiving novel agents and auto-HCT usually present with fever,
skin rash and include a transient engraftment syndrome (ES) or
more serious complications, Graft vs. Host Disease (GvHD) and
DRESS (drug rash with eosinophilia and systemic syndrome) with
the latter two requiring specific therapies.The clinical characteristics
of these 3 syndromes may overlap, complicating patient manage-
ment. We evaluated a set of clinical and laboratory diagnostic crite-
ria, including a plasma cytokine (PC) panel, to help diagnose these
clinical syndromes.
Patients andMethods: A retrospective review of medical records of
MMpatients (pts) who developed a skin rash between 2007 and 2010
and on whom PC panels were obtained. Clinical findings including
fever, skin rash, results of skin biopsies (SBx), clinical recurrence of
symptoms during tapering of therapy were evaluated. Laboratory
values evaluated included eosinophilia, liver and renal function tests,
plasma cytokines levels {soluble interleukin -2 (IL-2) receptor,
IL-4,5,6,8,10, IFN g, TNF-a, Eotaxin-3 and Eosinophil derived
neurotoxin (EDN)}. The mean, median and range of lab results
were calculated.
Results: pts were categorized into 4 groups: DRESS (n 5 25),
GVHD (n 5 6), ES (n 5 4), simultaneous DRESS and GVHD
(n5 1) and controls (29 pts without AI phenomena). The incidence
of eosinophilia and liver dysfunctionwere significantly higher among
pts with DRESS vs. those with GvHD, ES and controls. SBx results
differed between pts with DRESS (spongiosis and/or increased eo-
sinophils, 95% of pts) and those with GvHD (67% had any 2 of
the following: interface dermatitis, baso-vacuolation or peri-vascular
lymphocyte infiltration). The mean of PC, characteristics of eosino-
phil involvement were significantly elevated among pts with DRESS
compared with GVHD, ES or controls including higher values for
IL-5 (31.9 pg/mL in DRESS vs. 4 pg/mL in control), eotaxin-3
(24.5 pg/mL vs. 13.3 pg/mL) and EDN (98.8ng/mL vs. 17.5ng/
mL). Recurrence of events was noted among 7 of 25 pts with DRESS
vs. 1 of 6 and none of 4 among those with GVHD and ES, respec-
tively.
